Remove Development Remove Drug Delivery Remove In-Vivo
article thumbnail

Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform

Pharma Mirror

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.

article thumbnail

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

pharmaphorum

It will enable them understand the biology of the BBB, explore the latest technological innovations and develop more predictive preclinical models. The Blood-Brain Barrier Summit is the industry’s first meeting dedicated to targeting the blood-brain barrier in order to develop clinically efficacious therapeutics for CNS indications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Conjugation and Labeling of Molecules: A Burgeoning Approach in Therapeutics Development and Molecular Imaging

Roots Analysis

The synergistic behavior achieved from the process circumvents the inherent limitation of the individual counterparts, such as short in vivo half-life, low solubility and immunogenicity. Moreover, it provides a better understanding of the disposition of the drug and its role in causing organ toxicity.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

article thumbnail

Liposome: A Novel Drug Delivery System

Roots Analysis

Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.

article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs).

DNA 52
article thumbnail

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. TLC599 is a non-opioid, proprietary BioSeizer ® sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.

Trials 40